



Average FY Product Sales Consensus

€m	2020a	2021e	2022e	2023e	2024e	2025e	2026e	Peak Sales	NPV*
Core Products									
Cimzia	1,799	1,874	1,938	1,957	1,832	1,575	1,346		5,239
Vimpat	1,451	1,537	928	634	541	486	438		2,102
Keppra	788	761	680	626	578	538	498		2,308
Briviact	288	349	420	486	544	590	550	620	1,931
Neupro	311	285	248	214	182	157	138		541
New products**									
Evenity		488	653	797	923	1,030	1,119	1,253	2,221
Nayzilam	26	52	75	96	116	130	134	161	416
Potential new product launches**									
Bimekizumab		66	308	638	998	1,385	1,730	2,625	7,193
Zilucoplan		1	27	128	297	426	611	1,158	2,088
Rozanolixizumab (Rozimab)		0	23	77	190	313	459	905	1,416
Dapimab		0	0	1	7	26	111		
Staccato alprazolam		0	0	7	25	75	119	272	
Bepranemab		0	0	7	40	121	212		

* If cell blank: not sufficient data available

**global sales, non-risk adj.

Median FY Product Sales Consensus

€m	2020a	2021e	2022e	2023e	2024e	2025e	2026e	Peak Sales	NPV*
Core Products									
Cimzia	1,799	1,870	1,938	1,952	1,837	1,554	1,319		5,126
Vimpat	1,451	1,536	929	633	545	483	400		2,357
Keppra	788	747	677	619	571	531	485		2,039
Briviact	288	346	418	484	548	590	565	613	1,693
Neupro	311	290	246	203	171	157	141		529
New products**									
Evenity		495	670	823	961	1,076	1,151	1,165	2,323
Nayzilam	26	49	70	90	116	130	134	150	428
Potential new product launches**									
Bimekizumab		42	293	669	1,003	1,372	1,736	2,501	5,842
Zilucoplan		0	0	121	283	454	591	1,192	2,115
Rozanolixizumab (Rozimab)		0	0	67	156	299	480	888	1,144
Dapimab		0	0	0	0	29	70		
Staccato alprazolam		0	0	0	23	75	94	255	
Bepranemab		0	0	0	26	101	184		

* If cell blank: not sufficient data available

**global sales, non-risk adj.

Based on the estimates of 16 brokers

Last updated: 15/07/21